Altimmune, Inc. (ALT)
ALT Price and Sentiment
ALT Latest news
Altimmune has been one of the top-performing stocks in our speculative portfolio. The company recently reported encouraging results from their NASH candidate, ALT-801. The market has been bullish on ALT since they announced their COVID-19 programs, but now it is time to turn our attention to ALT-801. I believe ALT-801 is their flagship.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT2021-10-15 21:35
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S.
GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences:
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT2021-10-01 17:15
New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 20212021-09-29 18:15
GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST.
H.C. Wainwright said that Altimmune Inc (NASDAQ:ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients. However, shares dropped, which he sees primarily because one patient experienced elevated ALT levels that resolved after a pause in dosing.
Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.
The stock price of Altimmune Inc (NASDAQ: ALT) fell by over 19% during intraday trading today. This is why it happened.
Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.
Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. At 12 weeks, those who received pemvidutide achieved mean weight losses of 4.9%, 10.3%, and 9.0% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, compared to 1.6% weight loss in the placebo group.